Pioneering diagnostics

Publications in Immunoassay Field

BIONEXIA®

In Vitro Evaluation and Comparison of 5 Rapid Antigen Detection Tests for the Diagnosis of Beta-Hemolytic Group A Streptococcal Pharyngitis
Plainvert C, Duquesne I, Touak G, Dmytruk N, Poyart C.
Diagnostic Microbiology and Infectious Disease 2015

VIDAS® (Automated Immunoassay System)

VIDAS® B.R.A.H.M.S PCTTM

Use of a Combination Biomarker Algorithm To Identify Medical Intensive Care Unit Patients With Suspected Sepsis at Very Low Likelihood of Bacterial Infection
Han JH, Nachamkin I, Coffin SE, Gerber JS, Fuchs B, Garrigan C, Han X, Bilker WB, Wise J, Tolomeo P, Lautenbach E.
Antimicrobial Agents and Chemotherapy 2015

Economic Evaluation of Procalcitonin-Guided Antibiotic Therapy in Acute Respiratory Infections: a US Health System Perspective
Schuetz P, Balk R, Briel M, Kutz A, Christ-Crain M, Stolz D, Bouadma L, Wolff M, Kristoffersen KB, Wei L, Burkhardt O, Welte T, Schroeder S, Nobre V, Tamm M, Bhatnagar N, Bucher HC, Luyt CE, Chastre J, Tubach F, Mueller B, Lacey MJ, Ohsfeldt RL, Scheibling CM, Schneider JE.
Clinical Chemistry and Laboratory Medicine 2015

Impact of the Lab-Score on Antibiotic Prescription Rate in Children with Fever without Source: a Randomized Controlled Trial
Lacroix L, Manzano S, Vandertuin L, Hugon F, Galetto-Lacour A, Gervaix A.
PloS One 2014

Effectiveness and Safety of Procalcitonin-Guided Antibiotic Therapy in Lower Respiratory Tract Infections in “Real Life” (ProREAL study)
Albrich WC, Dusemund F, Bucher B, Meyer S, Thomann R, Kühn F, Bassetti S,  Sprenger M, Bachli E, Sigrist T, Schwietert M, Amin D, Hausfater P, Carre E, Gaillat J, Schuetz P, Regez K, Bossart R, Schild U, Mueller B.
Archives of Internal Medicine 2012;172:715-722.

Influence of major cardiopulmonary surgery on serum levels of procalcitonin and other inflammatory markers
Amin DN, Pruitt JC, Schuetz P.
Anaesth Intensive Care 2012;40:760-6

Influence of Procalcitonin on decision to start antibiotic treatment in patients with a lower respiratory tract infection: insight from the observational multicentric ProREAL surveillance
Dusemund F, Bucher B, Meyer S, Thomann R, Kühn F, Bassetti S, Sprenger M, Baechli E, Sigrist T, Schwietert, Amin D, Hausfater P, Carre E, Schuetz P, Gaillat J, Regez K, Bossart R, Schild U, Müller B, Albrich WC.
European Journal of Clinical Microbiology and Infectious Diseases 2012;32:51-60

Impact of the Use of Procalcitonin Assay in Hospitalized Adult Patients with Pneumonia at a Community Acute Care Hospital
Kook JL, Chao SR  Le J, Robinson PA.
Infection Control and Hospital Epidemiology 2012;33:424-426

Procalcitonin measurement for detection of serious bacterial infection in febrile children: Comparison between two automated immunoassays
Lacroix L, Manzano S, Galetto A, Gervaix A.
Clinical Biochemistry 2012;45:593-595

Rapid Response Team-Triggered Procalcitonin Measurement Predicts Infectious ICU Transfers
Wunderink RG, Diederich ER, Caramez MP, Donnelly HK, Norwood SD, Kho A, Reed KD.
Critical Care Medicine 2012;40:2090–2095

VIDAS® C. difficile GDH

The Role of Glutamate Dehydrogenase (GDH) Testing Assay in the Diagnosis of Clostridium Difficile Infections: A High Sensitive Screening Test and an Essential Step in the Proposed Laboratory Diagnosis Workflow for Developing Countries like China
Cheng JW, Xiao M, Kudinha T, Xu ZP, Sun LY, Hou X, Zhang L, Fan X, Kong F, Xu YC.
PloS One 2015

Comparison of the Vidas C. Difficile GDH Automated Enzyme-Linked Fluorescence Immunoassay (ELFA) with Another Commercial Enzyme Immunoassay (EIA) (Quik Chek-60), Two Selective Media, and a PCR Assay for GluD for Detection of Clostridium Difficile in Fecal Samples
Davies KA, Berry CE, Morris KA, Smith R, Young S, Davis TE, Fuller DD, Buckner RJ, Wilcox MH.
Journal of Clinical Microbiology 2015

VIDAS® CMV IgG Avidity

Comparison of the VIDAS® System and Two Recent Fully Automated Assays for Diagnosis and Follow-Up of Toxoplasmosis in Pregnant Women and Newborns
Murat J.B., Dard C., Fricker H.H., Darde M.L., Brenier-Pinchart M.P., Pelloux H.
Clinical and Vaccine Immunology : CVI 2013

Re-Evaluation of the VIDAS® Cytomegalovirus (CMV) IgG Avidity Assay: Determination of New Cut-Off Values Based on the Study of Kinetics of CMV-IgG Maturation
Vauloup-Fellous C., Berth M., Heskia F., Dugua J.M., Grangeot-Keros L.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology 2013

Re-evaluation of the VIDAS® cytomegalovirus (CMV) IgG avidity assay: determination of new cut-off values based on the study of kinetics of CMV-IgG avidity maturation.
Vauloup-Fellous C, Berth M, Heskia F, Dugua JM
Journal of Clinical Virology 2012

VIDAS® D-Dimer 

Age-Adjusted D-Dimer Cutoff Levels to Rule Out Pulmonary Embolism: the ADJUST-PE Study
Righini M, van Es J, Den Exter PL, Roy PM, Verschuren F, Ghuysen A, Rutschmann OT, Sanchez O, Jaffrelot M, Trinh-Duc A, Le Gall C, Moustafa F, Principe A, van Houten AA, Ten WM, Douma RA, Hazelaar G, Erkens PM, van Kralingen KW, Grootenboers MJ, Durian MF, Cheung YW, Meyer G, Bounameaux H, Huisman MV, Kamphuisen PW, Le Gal G.
JAMA : the Journal of the American Medical Association 2014

VIDAS® EBV

Determination of EBV Serostatus Prior to Kidney Transplantation: Comparison of VIDAS® , LIAISON® and Immunofluorescence Assays
Johannessen I, Noel M, Galloway A, Black S, Shearman M, Graham C.
Journal of Virological Methods 2014

Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status
Lupo J, Germi R, Semenova T, Buisson M, Seigneurin JM, Morand P.
Clinical and Vaccine Immunology 2012

Performance of the VIDAS® automated immunoassay for the determination of Epstein-Barr virus serological status
De Ory F, Guisasola ME, Sanz JC, Garci-Bermejo I.
Enferm Infecc Microbiol Clin 2012 (publication in Spanish)

VIDAS® Galectin-3

The Prognostic Value of Plasma Galectin-3 in Chronic Heart Failure Patients Is Maintained When Treated With Mineralocorticoid Receptor Antagonists
Koukoui F, Desmoulin F, Galinier M, Barutaut M, Caubere C, Evaristi MF, Murat G, de Boer R, Berry M, Smih F, Rouet P.
PloS One 2015

Biomarker-Assist Score for Reverse Remodeling Prediction in Heart Failure: The ST2-R2 Score
Lupon J, Gaggin HK, de Antonio M, Domingo M, Galan A, Zamora E, Vila J, Penafiel J, Urrutia A, Ferrer E, Vallejo N, Januzzi JL, Bayes-Genis A.
International Journal of Cardiology 2015

Prognostic Value of the Interaction Between Galectin-3 and Antigen Carbohydrate 125 in Acute Heart Failure
Nunez J, Rabinovich GA, Sandino J, Mainar L, Palau P, Santas E, Villanueva MP, Nunez E, Bodi V, Chorro FJ, Minana G, Sanchis J.
PloS One 2015

Circulating Microribonucleic Acids MiR-1, MiR-21 and MiR-208a in Patients With Symptomatic Heart Failure: Preliminary Results
Sygitowicz G, Tomaniak M, Blaszczyk O, Koltowski L, Filipiak KJ, Sitkiewicz D.
Archives of Cardiovascular Diseases 2015

Galectin-3 Predicts Short- and Long-Term Outcome in Patients Undergoing Transcatheter Aortic Valve Implantation (TAVI) Baldenhofer G, Zhang K, Spethmann S, Laule M, Eilers B, Leonhardt F, Sanad W, Dreger H, Sander M, Grubitzsch H, Baumann G, Stangl K, Stangl V, Knebel F.
International Journal of Cardiology 2014

Galectin-3 Testing: Validity of a Novel Automated Assay in Heart Failure Patients With Reduced Ejection Fraction
Gruson D., Mancini M., Ahn S.A., Rousseau M.F.
Clinica Chimica Acta; International Journal of Clinical Chemistry 2013

The Association Between Galectin-3 and Clinical Parameters in Patients With First Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Angioplasty
Szadkowska I., Wlazel R.N., Migala M., Szadkowski K., Zielinska M., Paradowski M., Pawlicki L.
Cardiology Journal 2013

The Association Between Galectin-3 and Occurrence of Reinfarction Early After First Myocardial Infarction Treated Invasively
Szadkowska I., Wlazel R.N., Migala M., Bajon-Laskowska K., Szadkowski K., Zielinska M., Paradowski M., Pawlicki L.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals 2013

VIDAS® NT-proBNP

Measurement of Natriuretic Peptides at the Point of Care in the Emergency and Ambulatory Setting: Current Status and Future Perspectives
Bingisser R., Cairns C.B., Christ M., Collinson P., Hausfater P., Lindahl B., Mair J., Price C., Venge P.
American Heart Journal 2013

VIDAS® ToRC

Analytical Issues Possibly Affecting the Performance of Commercial Human Cytomegalovirus IgG Avidity Assays
Berth M., Grangeot-Keros L., Heskia F., Dugua JM, Vauloup-Fellous C.
European Journal of Clinical Microbiology and Infectious Diseases 2014

Comments on an Alternative Calculation of Cytomegalovirus IgG Avidity Indexes on VIDAS®
Berth M, Grangeot-Keros L, Heskia F, Dugua JM, Vauloup-Fellous C.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology 2014

VIDAS® Troponin I

Cardiac Troponin Assay Classification by Both Clinical and Analytical Performance Characteristics: a Study on Outcome Prediction
Venge P., Lindahl B.
Clinical Chemistry 2013

Cardiac troponin: a critical review of the case for point-of-care testing in the emergency department
Bingisser R, Caires C, Christ M, Hausfater P, Lindahl B, Mair J, Panteghini M, Price C, Venge P.
American Journal of Emergency Medicine 2012

VIDAS® 25 OH Vitamin D Total

Performance Characteristics of the VIDAS(R) 25-OH Vitamin D Total Assay - Comparison With Four Immunoassays and Two Liquid Chromatography-Tandem Mass Spectrometry Methods in a Multicentric Study
Moreau E, Bacher S, Mery S, Goff CL, Piga N, Vogeser M, Hausmann M, Cavalier E.
Clinical Chemistry and Laboratory Medicine 2015

Comparison of Cord Blood Vitamin D Levels in Newborns of Vitamin D Supplemented and Unsupplemented Pregnant Women: a Prospective, Comparative Study
Nandal R, Chhabra R, Sharma D, Lallar M, Rathee U, Maheshwari P.
The Journal of Maternal-Fetal & Neonatal Medicine 2015

Critical Care and Vitamin D Status Assessment: What About Immunoassays and Calculated Free 25OH-D?
Rousseau AF, Damas P, Janssens M, Kalin S, Ledoux D, Le GC, Gadisseur R, Delanaye P, Cavalier E.
Clinica Chimica Acta; International Journal of Clinical Chemistry 2014

VIKIA® (Rapid Testing)

VIKIA® HBs Ag

Validation of Rapid Point-of-Care (POC) Tests for Detection of Hepatitis B Surface Antigen in Field and Laboratory Settings in the Gambia, Western Africa
Njai HF, Shimakawa Y, Sanneh B, Ferguson L, Ndow G, Mendy M, Sow A, Lo G, Toure-Kane C, Tanaka J, Taal M, D'alessandro U, Njie R, Thursz M, Lemoine M.
Journal of Clinical Microbiology 2015

Comparative Performance of Three Rapid HBsAg Assays for Detection of HBs Diagnostic Escape Mutants in Clinical Samples
Servant-Delmas A, Duong LT, Hamon C, Houdah AK, Laperche S.
Journal of Clinical Microbiology 2015

VIKIA® Malaria Ag Pf/Pan 

Malaria Rapid Diagnostic Test As Point-of-Care Test: Study Protocol for Evaluating the VIKIA Malaria Ag Pf/Pan
Kim S, Nhem S, Dourng D, Menard D.
Malaria Journal 2015

Evaluation of the Malaria Rapid Diagnostic Test VIKIA® Malaria Ag Pf/Pan in Endemic and Non-Endemic Settings
Eibach D., Traore B., Bouchrik M., Coulibaly B., Coulibaly N., Siby F., Bonnot G., Bienvenu A.L., Picot S.
Malaria Journal 2013

Performance of “VIKIA® Malaria Ag Pf/Pan” (IMACCESS), a new malaria rapid diagnostic test for detection of symptomatic malaria infections
Chou M, Kim S, Khim N, Chy S, Sum S, Dourng D, Canier L, Nguon C, Menard D.
Malaria Journal 2012

VIKIA® Rota-Adeno

Diagnostic Accuracy of Seven Commercial Assays for Rapid Detection of Group A Rotavirus Antigens
Kaplon J, Fremy C, Pillet S, Mendes ML, Ambert-Balay K, Aho SL, Pothier P.
Journal of Clinical Microbiology 2015

Note: The links in these documents will direct you away from this site. bioMérieux is not responsible for content of third party sites.